LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 32

Search options

  1. Article ; Online: Adolescent and Young Adult Cancer Biology.

    Tricoli, James V / Bleyer, Archie

    Cancer journal (Sudbury, Mass.)

    2018  Volume 24, Issue 6, Page(s) 267–274

    Abstract: Adolescent and young adult (AYA) patients with cancer have not attained the same improvements in overall survival as either younger children or older adults. One possible reason for this disparity may be that the AYA cancers exhibit unique biologic ... ...

    Abstract Adolescent and young adult (AYA) patients with cancer have not attained the same improvements in overall survival as either younger children or older adults. One possible reason for this disparity may be that the AYA cancers exhibit unique biologic characteristics, resulting in differences in clinical and treatment resistance behaviors. Our current understanding of the unique biological/genomic characteristics of AYA cancers is limited. However, there has been some progress that has provided clues about the biology of AYA cancers. We here review the latest findings in the area of AYA cancer biology and discuss what is required to advance the field for the more effective treatment of this patient population.
    MeSH term(s) Adolescent ; Adult ; Age Factors ; Genomics/methods ; Humans ; Medical Oncology/methods ; Neoplasm Staging ; Neoplasms/genetics ; Neoplasms/mortality ; Neoplasms/pathology ; Neoplasms/therapy ; Prognosis ; Treatment Outcome ; Young Adult
    Language English
    Publishing date 2018-11-27
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2018400-1
    ISSN 1540-336X ; 1528-9117 ; 1081-4442
    ISSN (online) 1540-336X
    ISSN 1528-9117 ; 1081-4442
    DOI 10.1097/PPO.0000000000000343
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 163: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.

    Chen, Monica F / Song, Zihe / Yu, Helena A / Sequist, Lecia V / Lovly, Christine M / Mitchell, Edith P / Moscow, Jeffrey A / Gray, Robert J / Wang, Victoria / McShane, Lisa M / Rubinstein, Larry V / Patton, David R / Williams, P Mickey / Hamilton, Stanley R / Umemura, Yoshie / Tricoli, James V / Conley, Barbara A / Arteaga, Carlos L / Harris, Lyndsay N /
    O'Dwyer, Peter J / Chen, Alice P / Flaherty, Keith T

    JCO precision oncology

    2024  Volume 8, Page(s) e2300454

    Abstract: Purpose: The National Cancer Institute Molecular Analysis for Therapy Choice trial is a signal-finding genomically driven platform trial that assigns patients with any advanced refractory solid tumor, lymphoma, or myeloma to targeted therapies on the ... ...

    Abstract Purpose: The National Cancer Institute Molecular Analysis for Therapy Choice trial is a signal-finding genomically driven platform trial that assigns patients with any advanced refractory solid tumor, lymphoma, or myeloma to targeted therapies on the basis of next-generation sequencing results. Subprotocol E evaluated osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with
    Methods: Eligible patients had
    Results: A total of 19 patients were enrolled: 17 were evaluable for toxicity and 13 for efficacy. The median age of the 13 included in the efficacy analysis was 63 years, 62% had Eastern Cooperative Oncology Group performance status 1, and 31% received >three previous systemic therapies. The most common tumor type was brain cancers (54%). The ORR was 15.4% (n = 2 of 13; 90% CI, 2.8 to 41.0) and 6-month PFS was 16.7% (90% CI, 0 to 34.4). The two confirmed RECIST responses were observed in a patient with neuroendocrine carcinoma not otherwise specified (
    Conclusion: In this pretreated cohort, osimertinib did not meet the prespecified end point threshold for efficacy, but responses were seen in a neuroendocrine carcinoma with an
    MeSH term(s) United States ; Humans ; Middle Aged ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/genetics ; National Cancer Institute (U.S.) ; Antineoplastic Agents/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Mutation ; Carcinoma, Neuroendocrine/drug therapy ; Acrylamides ; Aniline Compounds ; Indoles ; Pyrimidines
    Chemical Substances osimertinib (3C06JJ0Z2O) ; ErbB Receptors (EC 2.7.10.1) ; Antineoplastic Agents ; Protein Kinase Inhibitors ; Acrylamides ; Aniline Compounds ; Indoles ; Pyrimidines
    Language English
    Publishing date 2024-04-09
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.23.00454
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Phase II Study of Erdafitinib in Patients With Tumors With

    Gong, Jun / Mita, Alain C / Wei, Zihan / Cheng, Heather H / Mitchell, Edith P / Wright, John J / Ivy, S Percy / Wang, Victoria / Gray, Robert C / McShane, Lisa M / Rubinstein, Larry V / Patton, David R / Williams, P Mickey / Hamilton, Stanley R / Alva, Ajjai S / Tricoli, James V / Conley, Barbara A / Arteaga, Carlos L / Harris, Lyndsay N /
    O'Dwyer, Peter J / Chen, Alice P / Flaherty, Keith T

    JCO precision oncology

    2024  Volume 8, Page(s) e2300406

    Abstract: Purpose: Despite fibroblast growth factor receptor (: Methods: EAY131-K1 was an open-label, single-arm, phase II study with central confirmation of presence of : Results: Thirty-five patients were enrolled into this study with 18 included in the ... ...

    Abstract Purpose: Despite fibroblast growth factor receptor (
    Methods: EAY131-K1 was an open-label, single-arm, phase II study with central confirmation of presence of
    Results: Thirty-five patients were enrolled into this study with 18 included in the prespecified primary efficacy analysis. The median age of the 18 patients was 60 years, and 78% had received ≥3 previous lines of therapy. There were no confirmed responses to erdafitinib; however, five patients experienced stable disease (SD) as best response. One patient with an
    Conclusion: Erdafitinib did not meet its primary end point of efficacy as determined by ORR in treatment-refractory solid tumors harboring
    MeSH term(s) United States ; Humans ; Middle Aged ; Carcinoma, Transitional Cell ; National Cancer Institute (U.S.) ; Urinary Bladder Neoplasms/drug therapy ; Pyrazoles/therapeutic use ; Quinoxalines
    Chemical Substances erdafitinib (890E37NHMV) ; Pyrazoles ; Quinoxalines
    Language English
    Publishing date 2024-04-11
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.23.00406
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

    Gong, Jun / Mita, Alain C / Wei, Zihan / Cheng, Heather H / Mitchell, Edith P / Wright, John J / Ivy, S Percy / Wang, Victoria / Gray, Robert C / McShane, Lisa M / Rubinstein, Larry V / Patton, David R / Williams, P Mickey / Hamilton, Stanley R / Tricoli, James V / Conley, Barbara A / Arteaga, Carlos L / Harris, Lyndsay N / O'Dwyer, Peter J /
    Chen, Alice P / Flaherty, Keith T

    JCO precision oncology

    2024  Volume 8, Page(s) e2300407

    Abstract: Purpose: Subprotocol K2 (EAY131-K2) of the NCI-MATCH platform trial was an open-label, single-arm, phase II study designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 mutations ...

    Abstract Purpose: Subprotocol K2 (EAY131-K2) of the NCI-MATCH platform trial was an open-label, single-arm, phase II study designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 mutations or fusions.
    Methods: Central confirmation of tumor FGFR1-4 mutations or fusions was required for outcome analysis. Patients with urothelial carcinoma were excluded. Enrolled subjects received oral erdafitinib at a starting dose of 8 mg daily continuously until intolerable toxicity or disease progression. The primary end point was objective response rate (ORR) with key secondary end points of safety, progression-free survival (PFS), and overall survival (OS).
    Results: Thirty-five patients were enrolled, and 25 patients were included in the primary efficacy analysis as prespecified in the protocol. The median age was 61 years, and 52% of subjects had received ≥3 previous lines of therapy. The confirmed ORR was 16% (4 of 25 [90% CI, 5.7 to 33.0],
    Conclusion: This study met its primary end point in patients with several pretreated solid tumor types harboring FGFR1-3 mutations or fusions. These findings support advancement of erdafitinib for patients with fibroblast growth factor receptor-altered tumors outside of currently approved indications in a potentially tumor-agnostic manner.
    MeSH term(s) Humans ; Middle Aged ; Carcinoma, Transitional Cell ; Urinary Bladder Neoplasms/drug therapy ; Pyrazoles/therapeutic use ; Pyrazoles/adverse effects ; Mutation ; Quinoxalines
    Chemical Substances erdafitinib (890E37NHMV) ; Pyrazoles ; Quinoxalines
    Language English
    Publishing date 2024-04-11
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.23.00407
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.

    Connolly, Roisin M / Wang, Victoria / Hyman, David M / Grivas, Petros / Mitchell, Edith P / Wright, John J / Sharon, Elad / Gray, Robert J / McShane, Lisa M / Rubinstein, Larry V / Patton, David R / Williams, P Mickey / Hamilton, Stanley R / Wang, Jue / Wisinski, Kari B / Tricoli, James V / Conley, Barbara A / Harris, Lyndsay N / Arteaga, Carlos L /
    O'Dwyer, Peter J / Chen, Alice P / Flaherty, Keith T

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2024  Volume 30, Issue 7, Page(s) 1273–1280

    Abstract: Purpose: NCI-MATCH assigned patients with advanced cancer and progression on prior treatment, based on genomic alterations in pretreatment tumor tissue. Arm J (EAY131-J) evaluated the combination of trastuzumab/pertuzumab (HP) across HER2-amplified ... ...

    Abstract Purpose: NCI-MATCH assigned patients with advanced cancer and progression on prior treatment, based on genomic alterations in pretreatment tumor tissue. Arm J (EAY131-J) evaluated the combination of trastuzumab/pertuzumab (HP) across HER2-amplified tumors.
    Patients and methods: Eligible patients had high levels of HER2 amplification [copy number (CN) ≥7] detected by central next-generation sequencing (NGS) or through NCI-designated laboratories. Patients with breast/gastroesophageal adenocarcinoma and those who received prior HER2-directed therapy were excluded. Enrollment of patients with colorectal cancer was capped at 4 based on emerging data. Patients received HP IV Q3 weeks until progression or unacceptable toxicity. Primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS) and overall survival (OS).
    Results: Thirty-five patients were enrolled, with 25 included in the primary efficacy analysis (CN ≥7 confirmed by a central lab, median CN = 28). Median age was 66 (range, 31-80), and half of all patients had ≥3 prior therapies (range, 1-11). The confirmed ORR was 12% [3/25 partial responses (colorectal, cholangiocarcinoma, urothelial cancers), 90% confidence interval (CI) 3.4%-28.2%]. There was one additional partial response (urothelial cancer) in a patient with an unconfirmed ERBB2 copy number. Median PFS was 3.3 months (90% CI 2.0-4.1), and median OS 9.4 months (90% CI 5.0-18.9). Treatment-emergent adverse events were consistent with prior studies. There was no association between HER2 CN and response.
    Conclusions: HP was active in a selection of HER2-amplified tumors (non-breast/gastroesophageal) but did not meet the predefined efficacy benchmark. Additional strategies targeting HER2 and potential resistance pathways are warranted, especially in rare tumors.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/pathology ; Progression-Free Survival ; Receptor, ErbB-2/metabolism ; Trastuzumab/adverse effects ; Trastuzumab/therapeutic use
    Chemical Substances Antibodies, Monoclonal, Humanized ; pertuzumab (K16AIQ8CTM) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2024-03-04
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-0633
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Stable Acidic Water Oxidation with a Cobalt-Iron-Lead Oxide Catalyst Operating via a Cobalt-Selective Self-Healing Mechanism.

    Simondson, Darcy / Chatti, Manjunath / Bonke, Shannon A / Tesch, Marc F / Golnak, Ronny / Xiao, Jie / Hoogeveen, Dijon A / Cherepanov, Pavel V / Gardiner, James L / Tricoli, Antonio / MacFarlane, Douglas R / Simonov, Alexandr N

    Angewandte Chemie (International ed. in English)

    2021  Volume 60, Issue 29, Page(s) 15821–15826

    Abstract: The instability and expense of anodes for water electrolyzers with acidic electrolytes can be overcome through the implementation of a cobalt-iron-lead oxide electrocatalyst, [Co-Fe-Pb] ... ...

    Abstract The instability and expense of anodes for water electrolyzers with acidic electrolytes can be overcome through the implementation of a cobalt-iron-lead oxide electrocatalyst, [Co-Fe-Pb]O
    Language English
    Publishing date 2021-06-15
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2011836-3
    ISSN 1521-3773 ; 1433-7851
    ISSN (online) 1521-3773
    ISSN 1433-7851
    DOI 10.1002/anie.202104123
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Epigenetics of prostate cancer.

    McKee, Tawnya C / Tricoli, James V

    Methods in molecular biology (Clifton, N.J.)

    2015  Volume 1238, Page(s) 217–234

    Abstract: The introduction of novel technologies that can be applied to the investigation of the molecular underpinnings of human cancer has allowed for new insights into the mechanisms associated with tumor development and progression. They have also advanced the ...

    Abstract The introduction of novel technologies that can be applied to the investigation of the molecular underpinnings of human cancer has allowed for new insights into the mechanisms associated with tumor development and progression. They have also advanced the diagnosis, prognosis and treatment of cancer. These technologies include microarray and other analysis methods for the generation of large-scale gene expression data on both mRNA and miRNA, next-generation DNA sequencing technologies utilizing a number of platforms to perform whole genome, whole exome, or targeted DNA sequencing to determine somatic mutational differences and gene rearrangements, and a variety of proteomic analysis platforms including liquid chromatography/mass spectrometry (LC/MS) analysis to survey alterations in protein profiles in tumors. One other important advancement has been our current ability to survey the methylome of human tumors in a comprehensive fashion through the use of sequence-based and array-based methylation analysis (Bock et al., Nat Biotechnol 28:1106-1114, 2010; Harris et al., Nat Biotechnol 28:1097-1105, 2010). The focus of this chapter is to present and discuss the evidence for key genes involved in prostate tumor development, progression, or resistance to therapy that are regulated by methylation-induced silencing.
    MeSH term(s) DNA Methylation ; Epigenomics/methods ; Histone Deacetylases/metabolism ; Histones/genetics ; Histones/metabolism ; Humans ; Male ; MicroRNAs/genetics ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism
    Chemical Substances Histones ; MicroRNAs ; Histone Deacetylases (EC 3.5.1.98)
    Language English
    Publishing date 2015
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 1940-6029
    ISSN (online) 1940-6029
    DOI 10.1007/978-1-4939-1804-1_11
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: The NCI-MATCH trial: lessons for precision oncology.

    O'Dwyer, Peter J / Gray, Robert J / Flaherty, Keith T / Chen, Alice P / Li, Shuli / Wang, Victoria / McShane, Lisa M / Patton, David R / Tricoli, James V / Williams, P Mickey / Iafrate, A John / Sklar, Jeffrey / Mitchell, Edith P / Takebe, Naoko / Sims, David J / Coffey, Brent / Fu, Tony / Routbort, Mark / Rubinstein, Larry V /
    Little, Richard F / Arteaga, Carlos L / Marinucci, Donna / Hamilton, Stanley R / Conley, Barbara A / Harris, Lyndsay N / Doroshow, James H

    Nature medicine

    2023  Volume 29, Issue 6, Page(s) 1349–1357

    Abstract: The NCI-MATCH (Molecular Analysis for Therapy Choice) trial ( NCT02465060 ) was launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial-largely for patients with treatment-refractory, malignant solid tumors. Having ... ...

    Abstract The NCI-MATCH (Molecular Analysis for Therapy Choice) trial ( NCT02465060 ) was launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial-largely for patients with treatment-refractory, malignant solid tumors. Having completed in 2023, it remains one of the largest tumor-agnostic, precision oncology trials undertaken to date. Nearly 6,000 patients underwent screening and molecular testing, with a total of 1,593 patients (inclusive of continued accrual from standard next-generation sequencing) being assigned to one of 38 substudies. Each substudy was a phase 2 trial of a therapy matched to a genomic alteration, with a primary endpoint of objective tumor response by RECIST criteria. In this Perspective, we summarize the outcomes of the initial 27 substudies in NCI-MATCH, which met its signal-seeking objective with 7/27 positive substudies (25.9%). We discuss key aspects of the design and operational conduct of the trial, highlighting important lessons for future precision medicine studies.
    MeSH term(s) Humans ; Neoplasms/genetics ; Neoplasms/therapy ; Precision Medicine ; Medical Oncology ; Genomics ; High-Throughput Nucleotide Sequencing
    Language English
    Publishing date 2023-06-15
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-023-02379-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4212: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 39: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.

    Chi, Susan N / Yi, Joanna S / Williams, P Mickey / Roy-Chowdhuri, Sinchita / Patton, David R / Coffey, Brent D / Reid, Joel M / Piao, Jin / Saguilig, Lauren / Alonzo, Todd A / Berg, Stacey L / Ramirez, Nilsa C / Jaju, Alok / Mhlanga, Joyce C / Fox, Elizabeth / Hawkins, Douglas S / Mooney, Margaret M / Takebe, Naoko / Tricoli, James V /
    Janeway, Katherine A / Seibel, Nita L / Parsons, D Williams

    Journal of the National Cancer Institute

    2023  Volume 115, Issue 11, Page(s) 1355–1363

    Abstract: Background: National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice assigns patients aged 1-21 years with refractory solid tumors, brain tumors, lymphomas, and histiocytic disorders to phase II trials of ... ...

    Abstract Background: National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice assigns patients aged 1-21 years with refractory solid tumors, brain tumors, lymphomas, and histiocytic disorders to phase II trials of molecularly targeted therapies based on detection of predefined genetic alterations. Patients whose tumors harbored EZH2 mutations or loss of SMARCB1 or SMARCA4 by immunohistochemistry were treated with EZH2 inhibitor tazemetostat.
    Methods: Patients received tazemetostat for 28-day cycles until disease progression or intolerable toxicity (max 26 cycles). The primary endpoint was objective response rate; secondary endpoints included progression-free survival and tolerability of tazemetostat.
    Results: Twenty patients (median age = 5 years) enrolled, all evaluable for response and toxicities. The most frequent diagnoses were atypical teratoid rhabdoid tumor (n = 8) and malignant rhabdoid tumor (n = 4). Actionable alterations consisted of SMARCB1 loss (n = 16), EZH2 mutation (n = 3), and SMARCA4 loss (n = 1). One objective response was observed in a patient with non-Langerhans cell histiocytosis with SMARCA4 loss (26 cycles, 1200 mg/m2/dose twice daily). Four patients with SMARCB1 loss had a best response of stable disease: epithelioid sarcoma (n = 2), atypical teratoid rhabdoid tumor (n = 1), and renal medullary carcinoma (n = 1). Six-month progression-free survival was 35% (95% confidence interval [CI] = 15.7% to 55.2%) and 6-month overall survival was 45% (95% CI = 23.1% to 64.7%). Treatment-related adverse events were consistent with prior tazemetostat reports.
    Conclusions: Although tazemetostat did not meet its primary efficacy endpoint in this population of refractory pediatric tumors (objective response rate = 5%, 90% CI = 1% to 20%), 25% of patients with multiple histologic diagnoses experienced prolonged stable disease of 6 months and over (range = 9-26 cycles), suggesting a potential effect of tazemetostat on disease stabilization.
    MeSH term(s) United States/epidemiology ; Humans ; Child ; Child, Preschool ; National Cancer Institute (U.S.) ; Rhabdoid Tumor/drug therapy ; Rhabdoid Tumor/genetics ; Rhabdoid Tumor/diagnosis ; SMARCB1 Protein/genetics ; Benzamides/adverse effects ; DNA Helicases ; Nuclear Proteins ; Transcription Factors/genetics ; Enhancer of Zeste Homolog 2 Protein/genetics
    Chemical Substances tazemetostat (Q40W93WPE1) ; SMARCB1 Protein ; Benzamides ; SMARCA4 protein, human (EC 3.6.1.-) ; DNA Helicases (EC 3.6.4.-) ; Nuclear Proteins ; Transcription Factors ; SMARCB1 protein, human ; EZH2 protein, human (EC 2.1.1.43) ; Enhancer of Zeste Homolog 2 Protein (EC 2.1.1.43)
    Language English
    Publishing date 2023-05-25
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djad085
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.131: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Conference proceedings: MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis.

    Tricoli, James V / Jacobson, James W

    Cancer research

    2007  Volume 67, Issue 10, Page(s) 4553–4555

    MeSH term(s) Humans ; MicroRNAs/biosynthesis ; MicroRNAs/genetics ; Neoplasms/diagnosis ; Neoplasms/genetics ; Neoplasms/therapy ; Prognosis
    Chemical Substances MicroRNAs
    Language English
    Publishing date 2007-05-15
    Publishing country United States
    Document type Congresses
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-07-0563
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.135/5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top